We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Sensor Test Indicates Early Inflammation in Oral Cavity

By LabMedica International staff writers
Posted on 28 Aug 2017
Researchers have developed a novel rapid test using chewing gum and the tongue as a 24/7 detector, potentially providing a diagnostic device that could be used by nearly “anyone, anywhere, anytime”. More...
Their first such gum was successful in using saliva samples to identify patients with dental implants who had early-stage inflammation due to bacterial infection. Expanding this platform technology to other diseases could also provide more efficient screening of large populations.

Dental implants occasionally entail complications: in the years after receiving an implant 6-15% of patients develop an inflammatory response caused by bacteria, in the worst case destroying the soft tissue and bone around the implant. When the new test will be available (planned for in 2-3 years), patients would benefit from a simple, quick, and affordable method to assess whether they carry such bacteria.

The gum test was developed by a pharmaceutical research team at Julius-Maximilians-University Würzburg (JMU, Wurzburg, Germany) to provide early detection aimed at preventing serious complications. "Anyone can use this new diagnostic tool anywhere and anytime without any technical equipment," said Prof. Lorenz Meinel of JMU, who co-led the development with Dr. Jennifer Ritzer. Initial proof-of-principle studies using saliva of patients were conducted at Merli Dental Clinic in Rimini.

The scientific background: In the presence of inflammatory conditions, specific protein-degrading enzymes (matrix metalloproteinases) are activated in the mouth. While chewing the gum, these enzymes also rapidly break down the special ingredient in gum: peptide sensors consisting of a protease cleavable linker in between a bitter substance and a microparticle. When the peptide is cleaved, the bitter tasting substance is released and detected by the tongue. Patients can then visit their dentist who confirms the diagnosis and treats the disease.

Chewing gum rapid tests for other medical applications are presently under development. "We hope to be able to diagnose other diseases with our “anyone, anywhere, anytime” diagnostics to identify and address these diseases as early as possible," said Prof. Meinel.

The study, by Ritzer J et al, was published August 15, 2017, in the journal Nature Communications.

Related Links:
Julius-Maximilians-University Würzburg


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Immunofluorescence Analyzer
IFA System
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.